米国市場銘柄情報

NVCR ノボキュア

銘柄追加

12.635
+0.405+3.31%

終値 04/26 16:00 ET

12.550
-0.085-0.67%

市場後 19:46 ET

13.60億時価総額-6479直近PER

ノボキュアに関するコメント

ログインコメントを投稿

Kenneil Nugent

03/27 22:17

$ノボキュア(NVCR.US)$ pt anyone?

74338962

03/27 21:51

$ノボキュア(NVCR.US)$ I placed limit buy @13.1 but got filled at 13.299, I noticed this many times in this app, they are causing slippage, anyone noticed same?

zine1

03/27 20:52

$iBio Inc (IBIO.US)$ IBIO: 119% | IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for obesity and cardiometabolic diseases.
DRCT: -49% | Direct Digital Holdings shares are trading lower after the company reported worse-than-expected Q4 financial results.
NVCR: 42% | Novocure shares are trading higher after the company's METIS Phase 3 trial met primary endpoint, demonstrating statistically significant extension in time to intracranial ...

Movers and Shakers

03/27 20:28

コラムToday's Morning Movers and Top Ratings: MRNA, GME, MRK, CCL and More

Morning Movers
Gapping up
$ドイツ銀行(DB.US)$ shares rose 3% after Morgan Stanley upgraded the stock to overweight, suggesting further potential growth following a strong performance in 2024.
$メルク(MRK.US)$ stock rose 4.8% after its drug for treating a rare lung disease received FDA approval.
$トランプ・メディア・アンド・テクノロジー・グループ(DJT.US)$ stock jumped 14%, following gains after its Nasdaq debut.
$ロビンフッド・マーケッツ(HOOD.US)$ stock climbed 6...

mooster Han

03/27 20:06

Merck Soars, GameStop Plummets in Pre-Market Drama

Key Takeaway
GameStop ( $ゲームストップ(GME.US)$ ) and Forge Global ( $フォージ・グローバル・ホールディングス(FRGE.US)$ ) face pre-market declines of 17% and 11% respectively, while Novocure ( $ノボキュア(NVCR.US)$ ) surges 30% on positive trial results.
Merck ( $メルク(MRK.US)$ ) gains 4% after FDA approval of its treatment, highlighting a day of significant volatility and strategic moves in the U.S. stock market.
A Glimpse into Quarter-End Moves
As the curtains draw near on...

Moomoo AI

03/04 21:09

The 23% annualized share price decline underscores the risk of investing in unprofitable firms. The company's poor performance last year may suggest ongoing issues, as it was worse than the 11% annualized loss over the past five years. Prolonged share price weakness can be a negative indicator, though contrarian investors might want to investigate the stock for a potential turnaround.

NovoCure (NASDAQ:NVCR) Adds US$145m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 87%

Meltyy

03/04 17:54

Long hold

$ノボキュア(NVCR.US)$ FDA accepted their lung therapy application. Buying in at 14.00. Selling at 70.00. About a 5-6 month investment for over 300% profit.

まだコメントはありません

分析

アナリスト評価

データなし

目標株価

データなし

ホット

米国株

総合人気